Navigation Links
Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
Date:11/4/2010

BURLINGTON, Mass., Nov. 4, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar erosion of branded erythropoietin stimulating agent (ESA) market share is likely to be more rapid and more complete in the United States compared to biosimilar erosion seen in Europe since biosimilar ESAs entered the European market in 2007. According to Biosimilars Advisory Service: Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone, Decision Resources expects the timeline for the uptake of biosimilars among U.S. nephrologists will be fairly aggressive.

More than half of surveyed U.S. physicians anticipate they will begin prescribing a biosimilar ESA within six months of its launch and 88 percent expect to be using biosimilar ESAs within a year. In contrast, the majority of surveyed German nephrologists did not begin using biosimilar ESAs until the drugs had been on the market for 13-24 months. Uptake of biosimilars among surveyed French nephrologists has been even more conservative—60 percent of surveyed physicians report they still do not prescribe biosimilars ESAs.

Decision Resources forecasts that branded ESAs across the seven major pharmaceutical markets (U.S., France, Germany, Italy, Spain, United Kingdom and Japan) will lose $3 billion in combined sales to biosimilar erosion in 2019 alone, and $17.3 billion in combined sales to biosimilar erosion over Decision Resources' 2009-2019 forecast period.

"The global ESA market will be characterized by pricing pressures from a declining market and multiple biosimilar competitors," said Decision Resources Analyst MaryEllen Klusacek, Ph.D. "Biosimilars' lower costs compared with branded biologics will likely be the primary driver of both U.S. and European nephrologists' prescribing of biosimilar ESAs."

The Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German nephrologists and endocrinologists to highlight the key expectations that will drive or constrain biosimilar adoption.

Analyst CallMembers of the media are welcome to attend our upcoming analyst call entitled A Forecast of Biosimilars in Nephrology and Endocrinology: How Will Physicians' Perceptions of "Similarity" Affect Prescribing Behavior? This analyst call will be held on Friday, November 12 at 10 a.m. U.S. Eastern Time. For more information, contact Lisa Osgood at losgood@dresources.com.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.Decision ResourcesLisa Osgood781-993-2606losgood@dresources.comDecision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties
2. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
3. PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers
4. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
5. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
6. ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report
7. Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
8. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
9. The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies
10. Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019
11. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins a ... public.Where:  BTF,s Mobile MRI Unit – a 70 ... D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City Campaign ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
Breaking Medicine News(10 mins):